The Company and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2015

Basic and Diluted Net Income per Ordinary Share Computation

Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Numerator:
Net income (loss) attributable to Jazz Pharmaceuticals plc	$	87,960	$	25,766	$	246,774	$	(23,225	)
Denominator:
Weighted-average ordinary shares used in per share calculation - basic	61,435		60,305		61,145		59,457
Dilutive effect of employee equity incentive and purchase plans	1,719		2,288		1,927		—
Dilutive effect of warrants	—		87		—		—
Weighted-average ordinary shares used in per share calculation - diluted	63,154		62,680		63,072		59,457

Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic	$	1.43	$	0.43	$	4.04	$	(0.39	)
Diluted	$	1.39	$	0.41	$	3.91	$	(0.39	)

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share

The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):



	Three Months Ended September 30,		Nine Months Ended September 30,
	2015	2014	2015	2014
1.875% exchangeable senior notes due 2021	2,878	1,502	2,878	506
Options to purchase ordinary shares and RSUs	1,644	883	1,517	5,475
Warrants to purchase ordinary shares	—	—	—	618
Ordinary shares under ESPP	—	—	—	130